Patent ID: 6436407
Filing Date: 2002-08-20
Classification: A61K,C07K,C12N,Y02A,Y10S

Abstract:
A method of inducing both humoral and cellular immune responses to an HIV virus in a mammalian host, comprising administering an effective amount of an HIV antigen and an effective amount of an adjuvant comprising a mutant E. coli heat-labile enterotoxin holotoxin, in which arginine at amino acid position 192 is replaced with glycine, which holotoxin in substantially less toxic than native E. coli heat-labile enterotoxin holotoxin as measured in the Y-1 adrenal cell assay and which has immunologic adjuvant activity but lacks adenosine-di-phosphate (ADP) ribosylating enzymatic activity as measured by the nicotinamide-adenine-dinucleotide (NAD) Agmatine ADP-ribosyltransferase assay.